Ainos Inc - Company Profile
Powered by 
All the sales intelligence you need on Ainos Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ainos Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ainos Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ainos Inc (Ainos), formerly Amarillo Biosciences Inc, develops biologics for the treatment of human and animal diseases. The company develops innovative therapeutic candidates for the treatment of diseases such as neoplastic, influenza, hepatitis C, thrombocytopenia, viral diseases, autoimmune disorders and other indications using its core technology (proprietary low dose form) of natural human interferon alpha. Its product portfolio includes COVID-19 point-of-care tests, such as antigen rapid test, molecular rapid test and VOC-based point-of-care. The company primarily operates in the US and supplies its products and medical equipment in Taiwan, the People's Republic of China, and Hong Kong through its branches and provides food supplements and nutraceuticals in the Asian markets. Ainos is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
3050 Post Oak Blvd, Suite 510-T80, Houston, Texas, 77056
Website
www.ainos.com
Telephone
1 281 8986586
No of Employees
41
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AIMD (NASD)
Revenue (2024)
$124,200
498.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
0.6%
(2024 vs 2023)
Market Cap*
$11.3M
Net Profit Margin (2024)
XYZ
83.4%
(2024 vs 2023)
* As of and is in US$
Ainos Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Covid-19 POCT: | Veldona |
| Antigen Rapid Test | |
| VOC-based POCT: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In April, the company entered into a partnership with ASE Chung Li to power AI scent digitization in smart manufacturing. |
| 2025 | Contracts/Agreements | In March, the company entered into a partnership with Advanced Semiconductor Engineering Inc to power AI scent digitization in semiconductor manufacturing. |
| 2025 | Contracts/Agreements | In March, the company entered into a partnership with ugo Inc to develop the world's first robot with a sense of smell. |
Competitor Comparison
| Key Parameters | Ainos Inc | Regeneron Pharmaceuticals Inc | NRX Pharmaceuticals Inc | RenovoRx Inc | AIM ImmunoTech Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Houston | Tarrytown | Wilmington | Mountain View | Ocala |
| State/Province | Texas | New York | Delaware | California | Florida |
| No. of Employees | 41 | 15,410 | 29 | 17 | 19 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chun-Hsien Tsai | Chairman; Chief Executive Officer; President | Executive Board | 2021 | 56 |
| Christopher Lee | Chief Financial Officer | Senior Management | 2024 | - |
| Hsin-Liang Lee | Chief Financial Officer | Senior Management | 2024 | 55 |
| Chung-Yi Tsai | Director | Non Executive Board | 2021 | 50 |
| Ting-Chuan Lee | Director | Non Executive Board | 2021 | 43 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer